Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Aug 8;13(16):3999. doi: 10.3390/cancers13163999

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Dynamics of alpha diversity in EOC patients during chemotherapy based on therapeutic response and association with survival. (A) Boxplots showing the distribution of the number of observed ASVs during neoadjuvant (top) or adjuvant (bottom) chemotherapy. Patients were stratified by response to therapy: PR, platinum-resistant (left) vs. PS, platinum-sensitive (right). C, chemotherapy cycle. Wilcoxon test, * for p ≤ 0.05. (B) Kaplan–Meier curves for progression-free survival (left) and overall survival (right) in the whole cohort. EOC patients were stratified by higher or lower number of observed ASVs (relative to median) at the preC7 (for neoadjuvant therapy) or the preC4 (for adjuvant therapy) time-points. Log-rank test, p ≤ 0.1.